ProShares Ultra NASDAQ Biotechnology
30 hedge funds and large institutions have $26M invested in ProShares Ultra NASDAQ Biotechnology in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
88% more call options, than puts
Call options by funds: $22.2M | Put options by funds: $11.8M
11% more funds holding
Funds holding: 27 → 30 (+3)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
39% less capital invested
Capital invested by funds: $42.7M → $26M (-$16.7M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.93M |
| 2 |
OPPM
Opus Point Partners Management
New York
|
+$2.19M |
| 3 |
TH
Timber Hill
Greenwich,
Connecticut
|
+$1.21M |
| 4 |
ICAS
Investors Capital Advisory Services
Lynnfield,
Massachusetts
|
+$777K |
| 5 |
Jane Street
New York
|
+$554K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.96M |
| 2 |
BHA
Beech Hill Advisors
New York
|
-$1.04M |
| 3 |
AIG
American International Group
New York
|
-$836K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$429K |
| 5 |
BFC
Blue Fin Capital
Warren,
Rhode Island
|
-$370K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIG
26
American International Group
New York
| $30K | -$836K | -18,908 | -96% |
|
|
LTFS
27
Ladenburg Thalmann Financial Services
Miami,
Florida
| $4K | -$21.7K | -491 | -83% |
|
|
MFS
28
MSI Financial Services
Springfield,
Massachusetts
| $4K | – | – | – |
|
|
GWM
29
Geneos Wealth Management
Englewood,
Colorado
| $3K | +$3.67K | +83 | New |
|
|
BHA
30
Beech Hill Advisors
New York
| – | -$1.04M | -14,550 | Closed |
|
|
BFC
31
Blue Fin Capital
Warren,
Rhode Island
| – | -$370K | -5,182 | Closed |
|
32
Koshinski Asset Management
Decatur,
Illinois
| – | -$301K | -4,204 | Closed |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$13K | -180 | Closed |
|
BIB Hedge Fund Activity: Q1 2016 in Review
30 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2016, worth a combined $26M — down 39% from $42.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BIB positions and 4 closed out — a net gain of 4 holders — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $2.93M. The largest seller was Citadel Advisors, cutting an estimated $2.96M.
- 30 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2016, up from 27 in Q4 2015.
- Funds reported $26M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2016, down 39% quarter-over-quarter.
- 8 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2016 and 4 closed out, a net change of +4 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2016 was Tower Research Capital (TRC), an estimated $2.93M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2016 was Citadel Advisors, an estimated $2.96M sold.
Based on aggregated 13F filings for Q1 2016.